{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:12:09Z","timestamp":1767859929455,"version":"3.49.0"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense Breast Program","doi-asserted-by":"publisher","award":["W81XWH-06-1-0590"],"award-info":[{"award-number":["W81XWH-06-1-0590"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cure Foundation","award":["SAC100009"],"award-info":[{"award-number":["SAC100009"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006476","name":"Institute of Chemistry Timisoara of the Romanian Academy","doi-asserted-by":"publisher","award":["1.1\/2015"],"award-info":[{"award-number":["1.1\/2015"]}],"id":[{"id":"10.13039\/501100006476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.mce.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T21:23:38Z","timestamp":1433625818000},"page":"245-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"P3","title":["The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy"],"prefix":"10.1016","volume":"418","author":[{"given":"Ping","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp Y.","family":"Maximov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona F.","family":"Curpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balkees","family":"Abderrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2015.06.004_bib0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jama.1923.02650210074033","article-title":"An ovarian hormone","volume":"81","author":"Allen","year":"1923","journal-title":"J.\u00a0Am. Med. Assoc"},{"key":"10.1016\/j.mce.2015.06.004_bib0015","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2015.06.004_bib0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0025","doi-asserted-by":"crossref","first-page":"18879","DOI":"10.1073\/pnas.1115188108","article-title":"Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time","volume":"108","author":"Ariazi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib0030","first-page":"387","article-title":"Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance","volume":"37","author":"Balaburski","year":"2010","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1677\/erc.0.0060231","article-title":"Use of aromatase inhibitors in the adjuvant treatment of breast cancer","volume":"6","author":"Baum","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(83)90406-3","article-title":"Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer","volume":"2","author":"Baum","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0045","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0055","first-page":"7490","article-title":"Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens","volume":"63","author":"Bentrem","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0060","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jnci\/djq527","article-title":"Breast cancer risk in relation to the interval between menopause and starting hormone therapy","volume":"103","author":"Beral","year":"2011","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0070","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1073\/pnas.83.8.2496","article-title":"Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture","volume":"83","author":"Berthois","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib0075","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial","volume":"23","author":"Boccardo","year":"2005","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0080","first-page":"1161","article-title":"On oopherectomy in the cancer of the breast","volume":"ii","author":"Boyd","year":"1900","journal-title":"Br. Med. J."},{"key":"10.1016\/j.mce.2015.06.004_bib0085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.mce.2015.06.004_bib0090","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0095","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update","volume":"32","author":"Burstein","year":"2014","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.1993.175","article-title":"Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism","volume":"67","author":"Catherino","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0110","first-page":"1053","article-title":"A\u00a0naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog","volume":"9","author":"Catherino","year":"1995","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0120","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1128\/MCB.19.12.8226","article-title":"Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta","volume":"19","author":"Chang","year":"1999","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0125","doi-asserted-by":"crossref","first-page":"e89288","DOI":"10.1371\/journal.pone.0089288","article-title":"Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.mce.2015.06.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women\u2019s health initiative randomized clinical trials","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0135","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/0006-2952(83)90380-5","article-title":"Antiglucocorticoid properties of RU 38486 in a differentiated hepatoma cell line","volume":"32","author":"Chobert","year":"1983","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0140","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398","volume":"25","author":"Coates","year":"2007","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0145","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0140-6736(84)92795-8","article-title":"4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer","volume":"2","author":"Coombes","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0150","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A\u00a0randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7326\/0003-4819-103-3-324","article-title":"Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo","volume":"103","author":"Cummings","year":"1985","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0160","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2015.06.004_bib0165","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(85)90338-1","article-title":"Tamoxifen and contralateral breast cancer","volume":"2","author":"Cuzick","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0170","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0175","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01806795","article-title":"Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial","volume":"7","author":"Delozier","year":"1986","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0190","doi-asserted-by":"crossref","first-page":"djt337","DOI":"10.1093\/jnci\/djt337","article-title":"Final overall survival: fulvestrant 500\u2009mg vs 250\u2009mg in the randomized CONFIRM trial","volume":"106","author":"Di Leo","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/me.2007-0383","article-title":"27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator","volume":"22","author":"DuSell","year":"2008","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0205","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1210\/en.2010-0080","article-title":"The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis","volume":"151","author":"DuSell","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2015.06.004_bib0210","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"EBCTCG","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0215","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"EBCTCG","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"EBCTCG","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0225","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","article-title":"Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study","volume":"302","author":"Ellis","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2015.06.004_bib0230","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/0008-5472.CAN-12-0684","article-title":"Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment","volume":"72","author":"Fagan","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0235","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1990.8.4.599","article-title":"Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study","volume":"8","author":"Falkson","year":"1990","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0240","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/0008-5472.CAN-06-1020","article-title":"Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells","volume":"67","author":"Fan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0245","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1016\/j.ejca.2012.04.020","article-title":"Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines","volume":"48","author":"Fan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0250","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1158\/0008-5472.CAN-12-4152","article-title":"c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells","volume":"73","author":"Fan","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0255","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.ejca.2014.08.010","article-title":"Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells","volume":"50","author":"Fan","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0260","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.ejca.2014.08.011","article-title":"A\u00a0molecular model for the mechanism of acquired tamoxifen resistance in breast cancer","volume":"50","author":"Fan","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0265","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejca.2013.10.001","article-title":"Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells","volume":"50","author":"Fan","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/mend.15.1.0590","article-title":"Potentiation of estrogen receptor activation function 1 (AF-1) by Src\/JNK through a serine 118-independent pathway","volume":"15","author":"Feng","year":"2001","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib9010","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.mce.2015.06.004_bib0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1200\/JCO.1986.4.4.459","article-title":"Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial","volume":"4","author":"Fisher","year":"1986","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0280","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-106-5-649","article-title":"Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial","volume":"106","author":"Fisher","year":"1987","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0285","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0290","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0295","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0300","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(61)91088-1","article-title":"Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy","volume":"2","author":"Folca","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0315","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1042\/bj0720673","article-title":"Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep","volume":"72","author":"Glascock","year":"1959","journal-title":"Biochem. J."},{"key":"10.1016\/j.mce.2015.06.004_bib0320","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A\u00a0randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0325","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0330","first-page":"5183","article-title":"Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0335","first-page":"812","article-title":"Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0340","first-page":"4765","article-title":"Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in\u00a0vivo and in\u00a0vitro","volume":"49","author":"Gottardis","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0345","first-page":"4090","article-title":"Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens","volume":"49","author":"Gottardis","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0350","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1997.15.2.840","article-title":"Clinical potential of new antiestrogens","volume":"15","author":"Gradishar","year":"1997","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0355","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.3753802","article-title":"Sequence and expression of human estrogen receptor complementary DNA","volume":"231","author":"Greene","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.mce.2015.06.004_bib0360","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/1097-0142(197010)26:4<737::AID-CNCR2820260402>3.0.CO;2-T","article-title":"David A. Karnofsky memorial lecture. Thoughts on chemical therapy","volume":"26","author":"Haddow","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0365","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.2.4368.393","article-title":"Influence of synthetic oestrogens upon advanced malignant disease","volume":"2","author":"Haddow","year":"1944","journal-title":"Br. Med. J."},{"key":"10.1016\/j.mce.2015.06.004_bib0370","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.mce.2013.08.005","article-title":"Estrogen receptor beta in breast cancer","volume":"382","author":"Haldosen","year":"2014","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(88)92675-X","article-title":"Tamoxifen as risk factor for carcinoma of corpus uteri","volume":"2","author":"Hardell","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A\u00a0new derivative of triphenylethylene: effect on implantation and mode of action in rats","volume":"13","author":"Harper","year":"1967","journal-title":"J.\u00a0Reprod. Fertil"},{"key":"10.1016\/j.mce.2015.06.004_bib0385","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/oxfordjournals.annonc.a058286","article-title":"Response after withdrawal of tamoxifen and progestogens in advanced breast cancer","volume":"3","author":"Howell","year":"1992","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0390","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0400","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1210\/me.2002-0089","article-title":"Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists","volume":"16","author":"Huang","year":"2002","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0405","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1025484908380","article-title":"Oestrogen receptor-mediated modulation of the EGFR\/MAPK pathway in tamoxifen-resistant MCF-7 cells","volume":"81","author":"Hutcheson","year":"2003","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0410","first-page":"6539","article-title":"Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation","volume":"52","author":"Jeng","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3835(94)90001-9","article-title":"Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER","volume":"82","author":"Jeng","year":"1994","journal-title":"Cancer Lett"},{"key":"10.1016\/j.mce.2015.06.004_bib0420","first-page":"387","article-title":"Basic guides to the mechanism of estrogen action","volume":"18","author":"Jensen","year":"1962","journal-title":"Recent Prog. Horm. Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0425","first-page":"1980","article-title":"The estrogen receptor: a model for molecular medicine","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0430","first-page":"55","article-title":"Estrogen receptors and breast cancer response to adrenalectomy","volume":"34","author":"Jensen","year":"1971","journal-title":"Natl. Cancer Inst. Monogr"},{"key":"10.1016\/j.mce.2015.06.004_bib0435","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0440","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jnci\/84.8.580","article-title":"Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor","volume":"84","author":"Jiang","year":"1992","journal-title":"J.\u00a0Natl. Cancer Inst"},{"issue":"October Suppl.","key":"10.1016\/j.mce.2015.06.004_bib0445","first-page":"49","article-title":"Use of DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy","author":"Jordan","year":"1978","journal-title":"Rev. Endocr. Relat. Cancer"},{"issue":"Suppl.","key":"10.1016\/j.mce.2015.06.004_bib0450","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1007\/BF01855131","article-title":"Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications","volume":"3","author":"Jordan","year":"1983","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0455","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(25)06650-5","article-title":"Biochemical pharmacology of antiestrogen action","volume":"36","author":"Jordan","year":"1984","journal-title":"Pharmacol. Rev"},{"key":"10.1016\/j.mce.2015.06.004_bib0460","first-page":"267","article-title":"Laboratory models of breast cancer to aid the elucidation of antiestrogen action","volume":"109","author":"Jordan","year":"1987","journal-title":"J.\u00a0Lab. Clin. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0465","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/07357908809082124","article-title":"Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations","volume":"6","author":"Jordan","year":"1988","journal-title":"Cancer Invest"},{"key":"10.1016\/j.mce.2015.06.004_bib0470","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(88)90765-9","article-title":"Tamoxifen and endometrial cancer","volume":"2","author":"Jordan","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0475","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jnci\/90.13.967","article-title":"Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow","volume":"90","author":"Jordan","year":"1998","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0480","first-page":"5683","article-title":"Selective estrogen receptor modulation: a personal perspective","volume":"61","author":"Jordan","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.mce.2015.06.004_bib0485","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/jm020449y","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions","volume":"46","author":"Jordan","year":"2003","journal-title":"J.\u00a0Med. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0490","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/jm020450x","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents","volume":"46","author":"Jordan","year":"2003","journal-title":"J.\u00a0Med. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0495","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.mce.2015.06.004_bib0500","first-page":"S269","article-title":"Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer","volume":"147","author":"Jordan","year":"2006","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0505","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrc2048","article-title":"Chemoprevention of breast cancer with selective oestrogen-receptor modulators","volume":"7","author":"Jordan","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0510","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2007.11.002","article-title":"Tamoxifen: catalyst for the change to targeted therapy","volume":"44","author":"Jordan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0515","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1200\/JCO.2008.17.5190","article-title":"The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer\u2013survival or death?","volume":"26","author":"Jordan","year":"2008","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0520","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-14-0092","article-title":"Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer","volume":"21","author":"Jordan","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0525","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju296","article-title":"Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy","volume":"106","author":"Jordan","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0530","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju233","article-title":"Avoiding the bad and enhancing the good of soy supplements in breast cancer","volume":"106","author":"Jordan","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0535","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bcp.12440","article-title":"Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale","volume":"79","author":"Jordan","year":"2015","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0540","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-14-0448","article-title":"The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer","volume":"22","author":"Jordan","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0545","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0550","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.steroids.2006.10.009","article-title":"Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.mce.2015.06.004_bib0555","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/1940-6207.CAPR-11-0185","article-title":"Paradoxical clinical effect of estrogen on breast cancer risk: a \u201cnew\u201d biology of estrogen-induced apoptosis","volume":"4","author":"Jordan","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.mce.2015.06.004_bib0560","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1210\/endo-124-4-1717","article-title":"Regulation of prolactin synthesis in\u00a0vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone","volume":"124","author":"Jordan","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2015.06.004_bib0565","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1200\/JCO.2007.11.3886","article-title":"Selective estrogen-receptor modulators and antihormonal resistance in breast cancer","volume":"25","author":"Jordan","year":"2007","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0570","series-title":"Adjuvant Therapy of Cancer II","first-page":"19","article-title":"The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer","author":"Jordan","year":"1979"},{"key":"10.1016\/j.mce.2015.06.004_bib0575","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0026-895X(25)15094-3","article-title":"Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in\u00a0vitro","volume":"26","author":"Jordan","year":"1984","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0580","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1476-5381.1986.tb10174.x","article-title":"Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in\u00a0vitro","volume":"87","author":"Jordan","year":"1986","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0590","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/10408368809106860","article-title":"Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast","volume":"26","author":"Jordan","year":"1988","journal-title":"Crit. Rev. Clin. Lab. Sci"},{"key":"10.1016\/j.mce.2015.06.004_bib0595","first-page":"6619","article-title":"Molecular classification of estrogens","volume":"61","author":"Jordan","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.mce.2015.06.004_bib0600","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv075","article-title":"Estrogen receptor (ER) mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators (SERMs)","volume":"107","author":"Jordan","year":"2015","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0605","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tem.2005.01.004","article-title":"Transcription factor cross-talk: the estrogen receptor and NF-kappaB","volume":"16","author":"Kalaitzidis","year":"2005","journal-title":"Trends Endocrinol. Metab"},{"key":"10.1016\/j.mce.2015.06.004_bib0610","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.1953.63690120004013","article-title":"Effects of intensive sex steroid hormone therapy in advanced breast cancer","volume":"152","author":"Kennedy","year":"1953","journal-title":"J.\u00a0Am. Med. Assoc"},{"key":"10.1016\/j.mce.2015.06.004_bib0615","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume":"29","author":"Klinge","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0620","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/en.2005-0247","article-title":"Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor","volume":"146","author":"Knowlden","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2015.06.004_bib0625","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/me.2006-0203","article-title":"Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions","volume":"21","author":"Koide","year":"2007","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0630","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2005.07.001","article-title":"Synthetic progestins used in HRT have different glucocorticoid agonist properties","volume":"242","author":"Koubovec","year":"2005","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0635","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1073\/pnas.93.12.5925","article-title":"Cloning of a novel receptor expressed in rat prostate and ovary","volume":"93","author":"Kuiper","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib0640","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0092-8674(87)90581-2","article-title":"Functional domains of the human estrogen receptor","volume":"51","author":"Kumar","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.mce.2015.06.004_bib0645","first-page":"735","article-title":"A\u00a0comparative study of the carcinogenic action of certain oestrogenic hormones","volume":"28","author":"Lacassagne","year":"1936","journal-title":"Am. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0650","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/ajc.1936.217","article-title":"Hormonal pathogenesis of adenocarcinoma of the breast","volume":"27","author":"Lacassagne","year":"1936","journal-title":"Am. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0039-128X(02)00110-1","article-title":"Estrogen receptor phosphorylation","volume":"68","author":"Lannigan","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.mce.2015.06.004_bib0660","first-page":"1","article-title":"Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors","volume":"1","author":"Lathrop","year":"1916","journal-title":"J.\u00a0Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0665","first-page":"4893","article-title":"Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Lee","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0670","first-page":"4177","article-title":"Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0675","first-page":"1872","article-title":"The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor","volume":"58","author":"Levenson","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0680","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-0760(96)00184-7","article-title":"Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor","volume":"60","author":"Levenson","year":"1997","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0685","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/bjc.1998.301","article-title":"The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor","volume":"77","author":"Levenson","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0690","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0960-0760(00)00143-6","article-title":"Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351","volume":"76","author":"Levenson","year":"2001","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0695","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jsbmb.2004.12.032","article-title":"Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal","volume":"94","author":"Lewis","year":"2005","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0700","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/jnci\/dji400","article-title":"Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation","volume":"97","author":"Lewis","year":"2005","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0705","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.mce.2015.06.004_bib0710","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/S0021-9258(18)32483-9","article-title":"Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in\u00a0vitro","volume":"258","author":"Lieberman","year":"1983","journal-title":"J.\u00a0Biol. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0715","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1016\/S0021-9258(18)32484-0","article-title":"An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in\u00a0vitro","volume":"258","author":"Lieberman","year":"1983","journal-title":"J.\u00a0Biol. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0720","first-page":"3632","article-title":"Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex","volume":"61","author":"Liu","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0725","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.1074\/jbc.M108335200","article-title":"Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells","volume":"277","author":"Liu","year":"2002","journal-title":"J.\u00a0Biol. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0730","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jnci\/djg080","article-title":"Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in\u00a0vitro and in\u00a0vivo","volume":"95","author":"Liu","year":"2003","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0735","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/MCB.24.1.14-24.2004","article-title":"Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins","volume":"24","author":"Lonard","year":"2004","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0740","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/02841860903117816","article-title":"Additive endocrine therapy for advanced breast cancer \u2013 back to the future","volume":"48","author":"Lonning","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0745","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"Lonning","year":"2001","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib0750","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0755","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women","volume":"115","author":"Love","year":"1991","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0760","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0765","first-page":"5097","article-title":"Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351","volume":"60","author":"MacGregor Schafer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0770","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0960-0760(01)00072-3","article-title":"Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells","volume":"78","author":"MacGregor Schafer","year":"2001","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol"},{"key":"10.1016\/j.mce.2015.06.004_bib0775","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0780","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0785","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1021\/jm901907u","article-title":"Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen","volume":"53","author":"Maximov","year":"2010","journal-title":"J.\u00a0Med. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0790","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/HMBCI.2010.047","article-title":"The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis","volume":"5","author":"Maximov","year":"2011","journal-title":"Horm. Mol. Biol. Clin. Investig"},{"key":"10.1016\/j.mce.2015.06.004_bib0795","series-title":"Tamoxifen: Pioneering Medicine in Breast Cancer","author":"Maximov","year":"2013"},{"key":"10.1016\/j.mce.2015.06.004_bib0800","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0805","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1021\/jm500569h","article-title":"Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells","volume":"57","author":"Maximov","year":"2014","journal-title":"J.\u00a0Med. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-416673-8.00007-1","article-title":"Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story","volume":"93","author":"McDaniel","year":"2013","journal-title":"Vitam. Horm"},{"key":"10.1016\/j.mce.2015.06.004_bib0815","series-title":"Estrogen Receptors in Human Breast Cancer","author":"McGuire","year":"1975"},{"key":"10.1016\/j.mce.2015.06.004_bib0820","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1210\/endo.143.7.8892","article-title":"Minireview: nuclear receptor coactivators\u2013an update","volume":"143","author":"McKenna","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2015.06.004_bib0825","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0830","first-page":"814","article-title":"The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists","volume":"9","author":"Montano","year":"1995","journal-title":"Mol. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib0835","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0026-895X(25)09527-6","article-title":"Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in\u00a0vitro","volume":"38","author":"Murphy","year":"1990","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0840","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0026-895X(25)11001-8","article-title":"Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity","volume":"39","author":"Murphy","year":"1991","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0845","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jjco\/hyt203","article-title":"Soy intake and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population","volume":"44","author":"Nagata","year":"2014","journal-title":"Jpn. J. Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0850","first-page":"257","article-title":"Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation","volume":"1","author":"NATO","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0855","first-page":"836","article-title":"Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation","volume":"1","author":"NATO","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0860","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1241908","article-title":"27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology","volume":"342","author":"Nelson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mce.2015.06.004_bib0865","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1126\/science.285.5428.744","article-title":"Peptide antagonists of the human estrogen receptor","volume":"285","author":"Norris","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.mce.2015.06.004_bib0870","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/GME.0b013e31828865a5","article-title":"Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality","volume":"20","author":"Obiorah","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.mce.2015.06.004_bib0875","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/mol.113.089250","article-title":"Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer","volume":"85","author":"Obiorah","year":"2014","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0880","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/bjc.2014.50","article-title":"Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death","volume":"110","author":"Obiorah","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib0885","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1111\/bph.12762","article-title":"Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol","volume":"171","author":"Obiorah","year":"2014","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0890","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1940-6207.CAPR-14-0061","article-title":"Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state","volume":"7","author":"Obiorah","year":"2014","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.mce.2015.06.004_bib0895","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.270.5240.1354","article-title":"Sequence and characterization of a coactivator for the steroid hormone receptor superfamily","volume":"270","author":"Onate","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.mce.2015.06.004_bib0900","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0905","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jnci\/djg079","article-title":"Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer","volume":"95","author":"Osipo","year":"2003","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0910","first-page":"509","article-title":"Role for HER2\/neu and HER3 in fulvestrant-resistant breast cancer","volume":"30","author":"Osipo","year":"2007","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0915","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0920","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.286.6368.827","article-title":"Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute","volume":"286","author":"Ribeiro","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"key":"10.1016\/j.mce.2015.06.004_bib0925","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0277-5379(85)90104-X","article-title":"The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma\u20137-yr results","volume":"21","author":"Ribeiro","year":"1985","journal-title":"Eur. J. Cancer Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib0930","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.mce.2015.06.004_bib0935","first-page":"784","article-title":"In\u00a0vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in\u00a0vivo","volume":"48","author":"Robinson","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0940","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2015.06.004_bib0945","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/bies.10066","article-title":"Diversity in the mechanisms of gene regulation by estrogen receptors","volume":"24","author":"Sanchez","year":"2002","journal-title":"Bioessays"},{"key":"10.1016\/j.mce.2015.06.004_bib0950","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1210\/er.2008-0016","article-title":"History of aromatase: saga of an important biological mediator and therapeutic target","volume":"30","author":"Santen","year":"2009","journal-title":"Endocr. Rev"},{"key":"10.1016\/j.mce.2015.06.004_bib0955","first-page":"4308","article-title":"The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor","volume":"59","author":"Schafer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib0960","doi-asserted-by":"crossref","first-page":"13202","DOI":"10.1074\/jbc.M112215200","article-title":"Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen","volume":"277","author":"Schwartz","year":"2002","journal-title":"J.\u00a0Biol. Chem"},{"key":"10.1016\/j.mce.2015.06.004_bib0965","first-page":"171","article-title":"Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial","volume":"2","author":"SCTO","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2015.06.004_bib0970","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bph.12122","article-title":"Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells","volume":"169","author":"Sengupta","year":"2013","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.mce.2015.06.004_bib0975","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJM198510173131601","article-title":"Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens","volume":"313","author":"Shapiro","year":"1985","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib0980","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.mce.2015.06.004_bib0985","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju189","article-title":"The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study","volume":"106","author":"Shike","year":"2014","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0990","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib0995","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-12-3826","article-title":"Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer","volume":"19","author":"Skor","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1000","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2014.55.4139","article-title":"Past, present, and future challenges in breast cancer treatment","volume":"32","author":"Sledge","year":"2014","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib1005","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma","volume":"293","author":"Smith","year":"1975","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib1010","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/jnci\/93.22.1714","article-title":"Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol","volume":"93","author":"Song","year":"2001","journal-title":"J.\u00a0Natl. Cancer Inst"},{"key":"10.1016\/j.mce.2015.06.004_bib1015","series-title":"A\u00a0Good Man, Gregory Goodwin Pincus: The Man, His Story, the Birth Control Pill","author":"Speroff","year":"2009"},{"key":"10.1016\/j.mce.2015.06.004_bib1020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3892\/ijo.2014.2329","article-title":"Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells","volume":"44","author":"Sweeney","year":"2014","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.mce.2015.06.004_bib1025","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1158\/0008-5472.CAN-14-1784","article-title":"Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women\u2019s health initiative study","volume":"74","author":"Sweeney","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1030","first-page":"1012","article-title":"Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor","volume":"44","author":"Tate","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0022-4731(84)90240-1","article-title":"The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor","volume":"20","author":"Tate","year":"1984","journal-title":"J.\u00a0Steroid Biochem"},{"key":"10.1016\/j.mce.2015.06.004_bib1040","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A\u00a0comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib1045","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1073\/pnas.55.6.1574","article-title":"A\u00a0receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization","volume":"55","author":"Toft","year":"1966","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib1050","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1073\/pnas.57.6.1740","article-title":"A\u00a0receptor molecule for estrogens: studies using a cell-free system","volume":"57","author":"Toft","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib1055","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.mce.2015.06.004_bib1060","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nm1641","article-title":"27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen","volume":"13","author":"Umetani","year":"2007","journal-title":"Nat. Med"},{"key":"10.1016\/j.mce.2015.06.004_bib1065","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2015.06.004_bib1070","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.mce.2015.06.004_bib1075","first-page":"3867","article-title":"A\u00a0potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1080","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1073\/pnas.82.23.7889","article-title":"Cloning of the human estrogen receptor cDNA","volume":"82","author":"Walter","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2015.06.004_bib1085","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1078-0432.CCR-12-3771","article-title":"Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease","volume":"19","author":"Wardell","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-3-642-84745-5_4","article-title":"A\u00a0laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy","volume":"127","author":"Wolf","year":"1993","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00689683","article-title":"The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain","volume":"31","author":"Wolf","year":"1994","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.mce.2015.06.004_bib1100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6604145","article-title":"Epidemiology of soy exposures and breast cancer risk","volume":"98","author":"Wu","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mce.2015.06.004_bib1105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.celrep.2013.10.006","article-title":"27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth","volume":"5","author":"Wu","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.mce.2015.06.004_bib1110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mce.2008.08.001","article-title":"The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization","volume":"295","author":"Yang","year":"2008","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1016\/j.mce.2015.06.004_bib1115","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mce.2015.06.004_bib1120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex\u00a0vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.mce.2015.06.004_bib1125","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","article-title":"Increased risk of endometrial carcinoma among users of conjugated estrogens","volume":"293","author":"Ziel","year":"1975","journal-title":"N.\u00a0Engl. J. Med"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720715003111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720715003111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:52:35Z","timestamp":1748433155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720715003111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":225,"alternative-id":["S0303720715003111"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2015.06.004","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}